{
    "clinical_study": {
        "@rank": "38436", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }, 
            {
                "arm_group_label": "Active, nadolol", 
                "arm_group_type": "Experimental", 
                "description": "Active"
            }
        ], 
        "brief_summary": {
            "textblock": "To test the hypothesis that 11-15 week treatment with the inverse agonist nadolol will\n      improve smoking cessation in patients with COPD (chronic bronchitis dominant) compared to\n      placebo and standard of care."
        }, 
        "brief_title": "Efficacy and Safety of \u0392eta-adrenoceptor Inverse Agonist, Nadolol, In Smoking Cessation of Patients With Pre-existing COPD", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoking Cessation", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Active cigarette-smoking males and females between the ages of 18-70 with documented\n             physician-diagnosed COPD (chronic bronchitis dominant), as defined either by the\n             American Thoracic Society or the World Health Organization.\n\n          2. Desire to quit smoking in conjunction with participation in an approved smoking\n             cessation program administered by the participating sites. Enrollment in the smoking\n             cessation program must take place prior to Visit 3 (third dose escalation visit).\n\n          3. Pre-bronchodilator FEV1 between 55 and 70% of predicted\n\n          4. Baseline blood pressure \u2265 110/65mm Hg\n\n          5. Baseline heart rate \u2265 60 beats/min.\n\n          6. Smoking at least 10 cigarettes per day prior to participation in the approved smoking\n             cessation program.\n\n          7. Previous failure to quit smoking due to:\n\n               -  cough/ and or sputum, and/ or\n\n               -  sleep disturbance due to increased cough\n\n          8. Able to complete diary cards and comply with study procedures.\n\n          9. Females of childbearing age may participate only if they have a negative pregnancy\n             test, are non-lactating, and agree to practice an adequate birth control method\n             (abstinence, combination barrier and spermicide, or hormonal) for the duration of the\n             study.\n\n        Exclusion Criteria:\n\n        Subjects who meet ANY of the following criteria are not eligible for enrollment:\n\n          1. Diagnosis of asthma, cystic fibrosis, or PiZZ emphysema\n\n          2. Inability or unwillingness to give written informed consent\n\n          3. History of upper/lower respiratory tract infection, COPD exacerbation requiring\n             systemic steroids, antibiotics, and or ER visit or urgent care within 6 weeks of\n             Visit 1\n\n          4. History of adverse reaction or allergy to nadolol\n\n          5. History of neurological, hepatic, renal, or other medical conditions that may\n             interfere with the interpretation of data or the patient's participation in the study\n             or may increase safety concerns\n\n          6. History of cardiovascular diseases including uncontrolled hypertension (BP >160/100),\n             ischemic heart disease, congestive heart failure (NYHA III or IV), valvular heart\n             disease or cardiomyopathy\n\n          7. Known allergy or sensitivity to atropine or ipratropium bromide\n\n          8. Documented or self-reported current history of alcoholism or drug abuse\n\n          9. Participation in another research trial within 30 days of starting this trial\n\n         10. Unwillingness or inability to comply with study procedures\n\n         11. Inability to swallow the study medication capsule\n\n         12. Pregnant or nursing\n\n         13. Current use of any other beta-blocker medication, Verapamil or diltiazem\n             (non-dihydropyridine calcium channel blockers), OTC remedies containing\n             pseudoephedrine, ephedrine-based or containing dietary or herbal supplements, and or\n             ACE inhibitors.\n\n         14. Scheduled for surgery requiring general anaesthesia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825122", 
            "org_study_id": "INVSC001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active, nadolol", 
                "intervention_name": "Nadolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nadolol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "DKsiazek@dom.wustl.edu", 
                "last_name": "Deb Ksiazek"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Mario Castro, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "cornelius.pitts@inviongroup.com", 
            "last_name": "Cornelius Pitts, Pharm.D", 
            "phone": "215-518-0466"
        }, 
        "overall_official": {
            "affiliation": "Washington University of St. Louis", 
            "last_name": "Mario Castro, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in the average number of cigarettes smoked per day in a week", 
            "safety_issue": "No", 
            "time_frame": "Last 28 days on study medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Invion, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Invion, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}